Valuation: Vectura Group

Market Cap 1B 860M 803M 736M 1.38B 96.12B 1.41B 9.52B 3.71B 48.17B 3.77B 3.69B 159B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 796M 743M 682M 1.28B 89.01B 1.31B 8.82B 3.44B 44.61B 3.49B 3.42B 148B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
31/10/25 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
17/09/24 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
16/04/24 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
29/12/21 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
03/12/21 Philip Morris CEO does not need M&A to hit smoke free goals RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 01/06/2016
Corporate Secretary - 30/06/2025
Director TitleAgeSince
Director/Board Member 53 15/09/2023
Director/Board Member 57 30/06/2025

Financials

2019 2020
Net sales 178M 153M 142M 131M 246M 17.06B 250M 1.69B 659M 8.55B 669M 655M 28.31B 191M 163M 152M 140M 263M 18.24B 268M 1.81B 704M 9.14B 716M 700M 30.26B
Net income -22.1M -18.92M -17.65M -16.2M -30.44M -2.11B -31.04M -209M -81.64M -1.06B -82.98M -81.18M -3.51B 122M 105M 97.78M 89.72M 169M 11.71B 172M 1.16B 452M 5.87B 460M 450M 19.43B
Net Debt -66.5M -56.94M -53.12M -48.75M -91.6M -6.36B -93.4M -630M -246M -3.19B -250M -244M -10.56B -74.4M -63.7M -59.43M -54.54M -102M -7.12B -104M -705M -275M -3.57B -279M -273M -11.81B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-